a procedureCAR T-cell therapy

A patient's own T cells are collected from the blood, genetically modified in a factory to carry a receptor for a marker on their cancer, grown up, frozen, shipped back and infused after a short course of chemotherapy that clears room for them. The Kymriah label describes cells "obtained via a standard leukapheresis procedure", enriched, "transduced with the lentiviral vector containing the anti-CD19 CAR transgene", expanded, washed and cryopreserved. It is given once. The dangerous part is what the cells do in the fortnight after they go in.

CAR-T travels because of who is allowed to give it and where those places are, and the rules moved recently enough that most secondary accounts are out of date.

In the United States the products were dispensed only by hospitals specially certified under a Risk Evaluation and Mitigation Strategy, holding tocilizumab on site. On 26 June 2025 the Food and Drug Administration eliminated that scheme for all six autologous CAR-T products, removing "the requirement that hospitals and their associated clinics that dispense the above products are specially certified and have on-site, immediate access to tocilizumab". The Kymriah label's own change table records "KYMRIAH REMS (5.3) Removed 6/2025". A 2025 paper in Cancers records what the old rule required: "Patients were also required to remain within a two-hour radius of the treatment center for four weeks following infusion and to avoid driving for eight weeks. These logistical demands often necessitated temporary relocation, particularly for patients living in rural areas."

Europe did not follow. A survey of the thirty EEA countries and the United Kingdom, published in HemaSphere with a status date of August 2024, found that "in August 2024, 26% of the 31 countries had no CAR‐T products commercially available", that "the median number of qualified CAR‐T centers per 10 million population per country was 5.0", and that in 55% of the countries "centers were required to be transplant/JACIE‐accredited". Its centre table runs from 45 in Germany, 37 in Italy, 35 in France, 32 in Spain and 23 in the United Kingdom down to one apiece in Croatia, Hungary, Luxembourg, Norway, Slovakia and Slovenia — and none at all in Bulgaria, Cyprus, Estonia, Iceland, Latvia, Liechtenstein, Lithuania and Malta. Time from marketing authorisation to access ranged from a median of nought months in France and Germany to 53 in Slovakia.

So patients cross borders, and some health systems send them. The same paper: "some of these countries, including Latvia, Luxembourg, Iceland, and Malta, can send patients abroad to receive CAR‐T treatment." Its authors attach the caution this directory would attach anyway — that cross-border care "requires well‐structured cross‐border collaboration and that patients are able to travel abroad for a certain period, which may be logistically, physically, and/or emotionally burdensome."

Distance bites inside a country too. In one US institutional cohort of adults with large B-cell lymphoma, "52% of patients traveled more than 30 miles, 40% more than 60 miles, and 29% over 120 miles to reach treatment."

Apheresis first: the Kymriah medication guide says it "takes 3 to 6 hours and may need to be repeated". Manufacturing is quoted at "about 3-4 weeks from the time your cells are received at the manufacturing site and shipped back" — but the label's own trial reports a median 113 days, range 47 to 196, from apheresis to infusion in diffuse large B-cell lymphoma. Manufacture can fail: "this has been reported in up to 9% of manufacturing attempts". Lymphodepletion follows, on the Yescarta label "cyclophosphamide 500 mg/m2 intravenously and fludarabine 30 mg/m2 intravenously on the fifth, fourth, and third day before infusion". Then one infusion, and the watch: cytokine release syndrome "occurred in 90% (379/422) of patients with non-Hodgkin lymphoma", grade 3 or worse in 9%, median onset 2 days; neurologic toxicity in 78%, grade 3 or worse in 25%, median onset 4 days and median duration 17. The label instructs clinicians to "monitor patients at least daily for 7 days following infusion", to "instruct patients to remain within proximity of a healthcare facility for at least 2 weeks following infusion", and to advise against driving for the same two weeks. No distance appears anywhere in the current labels: proximity is left undefined.

Prices are published per product and per country, and they are not the cost of the episode. Novartis set the first list price at 475,000 US dollars in August 2017. Acquisition costs since have risen rather than fallen: a 2023 paper in Blood Advances records axicabtagene ciloleucel going "from $399 000 in 2022 to $424 000 in 2023 and liso-cel from $410 300 to $447 227 over the same period". The National Institute for Health and Care Excellence publishes the UK list price at £280,451 per single infusion bag and states that the discount the NHS actually pays "is commercial in confidence". Against those drug prices, US Medicare paid an average of 498,723 dollars for an inpatient CAR-T claim in 2021–2022, and 587,908 dollars across the whole episode of care. India approved its own product, NexCAR19, in October 2023; a 2024 paper reports it "is expected to cost 50,000 USD", which is an expectation in a journal and not a list price.

This page describes a treatment and the rules that govern where it may be given. It is not medical advice and it is not legal advice.